- Home
- OCS vs COLL Comparison
OCS vs COLL Comparison
Compare OCS & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCS
- COLL
- Stock Information
- Founded
- OCS 2003
- COLL 2002
- Country
- OCS Switzerland
- COLL United States
- Employees
- OCS N/A
- COLL N/A
- Industry
- OCS Biotechnology: Pharmaceutical Preparations
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- OCS Health Care
- COLL Health Care
- Exchange
- OCS Nasdaq
- COLL Nasdaq
- Market Cap
- OCS 904.3M
- COLL 910.2M
- IPO Year
- OCS N/A
- COLL 2015
- Fundamental
- Price
- OCS $18.66
- COLL $29.39
- Analyst Decision
- OCS Strong Buy
- COLL Strong Buy
- Analyst Count
- OCS 4
- COLL 5
- Target Price
- OCS $29.50
- COLL $43.60
- AVG Volume (30 Days)
- OCS 43.3K
- COLL 443.7K
- Earning Date
- OCS 03-11-2025
- COLL 05-08-2025
- Dividend Yield
- OCS N/A
- COLL N/A
- EPS Growth
- OCS N/A
- COLL 43.56
- EPS
- OCS N/A
- COLL 1.86
- Revenue
- OCS $757,024.00
- COLL $631,449,000.00
- Revenue This Year
- OCS $927.26
- COLL $20.00
- Revenue Next Year
- OCS $292.79
- COLL $3.93
- P/E Ratio
- OCS N/A
- COLL $15.65
- Revenue Growth
- OCS N/A
- COLL 11.41
- 52 Week Low
- OCS $10.55
- COLL $27.28
- 52 Week High
- OCS $23.08
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- OCS 38.58
- COLL 45.81
- Support Level
- OCS $18.30
- COLL $29.33
- Resistance Level
- OCS $19.98
- COLL $30.84
- Average True Range (ATR)
- OCS 0.67
- COLL 0.90
- MACD
- OCS 0.05
- COLL 0.03
- Stochastic Oscillator
- OCS 21.18
- COLL 35.98
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.